Vaxxinity

VAXXPhase 3

Vaxxinity is developing a next-generation immunotherapy platform to transform the treatment of chronic diseases and infectious threats. Its core AIM technology uses synthetic peptides to convert the body into its own 'drug factory,' stimulating targeted antibody production with a validated profile across billions of animal health doses and multiple human trials. The company is advancing a pipeline targeting large markets like Alzheimer's, Parkinson's, and COVID-19, with a strategic focus on creating accessible, scalable, and durable medicines that do not require complex frozen logistics.

Market Cap

$11K

Focus

RNA & Gene TherapyVaccines

VAXX · Stock Price

USD 0.004.01 (-100.00%)

Historical price data

AI Company Overview

Technology Platform

The Active Immunotherapy Medicine (AIM) platform uses synthetic peptides to overcome immune tolerance, stimulating the body's own production of durable, targeted antibodies against both self-antigens (for chronic diseases) and pathogens (for infectious diseases).

Pipeline Snapshot

8 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
UB-612 + BNT162b2 vaccine + ChAdOx1-S vaccine + Sinopharm BIBP	COVID-19 Vaccines	Phase 3
UB-612	Covid-19	Phase 2/3
UB-612 + Placebo	COVID-19	Phase 2
UB-313 + Placebo	Migraine	Phase 1
UB-312 + Placebo	Parkinson's Disease	Phase 1

Opportunities

Vaxxinity's primary growth opportunity lies in validating its AIM platform in Alzheimer's disease, which could unlock its application across numerous other chronic conditions like Parkinson's and hypercholesterolemia.

The platform's cost-effective, scalable, and logistically simple profile also presents a significant opportunity in global health markets for both chronic and infectious diseases.

Risk Factors

Key risks include clinical trial failure, particularly in complex neurological indications; potential safety concerns related to breaking immune tolerance; and significant financial risk as a pre-revenue company needing to fund expensive late-stage development in a competitive capital environment.

Competitive Landscape

Vaxxinity competes with major pharma in neurology (e.g., Biogen, Lilly) and infectious diseases (e.g., Pfizer, Moderna). Its main differentiation is the AIM platform's unique ability to actively immunize against self-antigens for chronic diseases, combined with practical advantages like conventional cold chain storage and synthetic, low-cost manufacturing.